Poul Geertsen

5.1k total citations · 1 hit paper
73 papers, 3.6k citations indexed

About

Poul Geertsen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Poul Geertsen has authored 73 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 27 papers in Pulmonary and Respiratory Medicine and 22 papers in Molecular Biology. Recurrent topics in Poul Geertsen's work include Renal cell carcinoma treatment (17 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Renal and related cancers (14 papers). Poul Geertsen is often cited by papers focused on Renal cell carcinoma treatment (17 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Renal and related cancers (14 papers). Poul Geertsen collaborates with scholars based in Denmark, United States and United Kingdom. Poul Geertsen's co-authors include Julie Gehl, Hans von der Maase, Chris Collins, Gregor Serša, Gerald C. O’Sullivan, Z Rudolf, M. Marty, Lluis M. Mir, V. Billard and Lars Bastholt and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Poul Geertsen

72 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Electrochemotherapy – An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study

2006 628 citations Julie Gehl, Poul Geertsen et al. profile →

Peers

Countries citing papers authored by Poul Geertsen

Since Specialization

Citations

This map shows the geographic impact of Poul Geertsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Poul Geertsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Poul Geertsen more than expected).

Fields of papers citing papers by Poul Geertsen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Poul Geertsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Poul Geertsen. The network helps show where Poul Geertsen may publish in the future.

Co-authorship network of co-authors of Poul Geertsen

This figure shows the co-authorship network connecting the top 25 collaborators of Poul Geertsen. A scholar is included among the top collaborators of Poul Geertsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Poul Geertsen. Poul Geertsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Stereotactic Ablative Radiation Therapy of Bone Metastases in an Oligometastatic Setting: One-Year Follow-Up of the BONY-M Phase 2 Trial 2025 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), (unknown), Olfred Hansen, Tine Bjørn Nielsen, (unknown), Mirjana Josipović, Laurids Østergaard Poulsen, (unknown), (unknown), (unknown), Marie Johansen, (unknown), (unknown), Rikke Løvendahl Eefsen, Eva Serup‐Hansen, Michael Brun Andersen, Poul Geertsen, Ivan R. Vogelius, C.F. Behrens, Gitte Fredberg Persson	0
2	Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study 2024 ·Clinical Cancer Research ·(unknown), Julia S. Johansen, Finn Ole Larsen, Susann Theile, Jane Preuss Hasselby, Gro Linno Willemoe, Torben Lorentzen, Kasper Madsen, Estrid Høgdall, Tim Svenstrup Poulsen, (unknown), Poul Geertsen, C.F. Behrens, Inge Marie Svane, Dorte Nielsen, Inna M. Chen	3
3	MR-guided stereotactic radiotherapy of infra-diaphragmatic oligometastases: Evaluation of toxicity and dosimetric parameters 2024 ·Radiotherapy and Oncology ·(unknown), Pia Krause Møller, Mirjana Josipović, (unknown), Uffe Bernchou, Eva Serup‐Hansen, Kasper Madsen, Parag J. Parikh, Joshua Kim, Poul Geertsen, C.F. Behrens, Ivan R. Vogelius, Mette Pøhl, Tine Schytte, Gitte Fredberg Persson	2
4	Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC) 2022 ·Journal of Clinical Oncology ·Inna M. Chen, Julia S. Johansen, Susann Theile, Jessica Xin Hjaltelin, (unknown), Søren Brunak, Jane Preuss Hasselby, Gro Linno Willemoe, Torben Lorentzen, Kasper Madsen, Benny Vittrup Jensen, (unknown), Poul Geertsen, C.F. Behrens, Christian Nolsøe, (unknown), Inge Marie Svane, Dorte Nielsen	68
5	Online adaptive radiotherapy of urinary bladder cancer with full re-optimization to the anatomy of the day: Initial experience and dosimetric benefits 2022 ·Radiotherapy and Oncology ·(unknown), C.F. Behrens, L. Calmels, C. David Sjöström, Poul Geertsen, (unknown), Eva Serup‐Hansen, Henriette Lindberg, Patrik Sibolt	55
6	Evaluation of an automated template-based treatment planning system for radiotherapy of anal, rectal and prostate cancer 2022 ·Technical Innovations & Patient Support in Radiation Oncology ·L. Calmels, Patrik Sibolt, (unknown), Eva Serup‐Hansen, Henriette Lindberg, (unknown), Gitte Fredberg Persson, C. David Sjöström, Poul Geertsen, C.F. Behrens	21
7	Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma 2021 ·Journal of Clinical Oncology ·David F. McDermott, Jae‐Lyun Lee, Georg A. Bjarnason, James Larkin, Rustem Gafanov, Mark D. Kochenderfer, Niels Viggo Jensen, Frede Donskov, Jahangeer Malik, Alexandr Poprach, Scott S. Tykodi, Teresa Alonso‐Gordoa, Daniel C. Cho, Poul Geertsen, Miguel Á. Climent Durán, Christopher DiSimone, Rachel Kloss Silverman, Rodolfo F. Perini, Charles Schloss, Michael B. Atkins	90
8	Single-isocenter stereotactic non-coplanar arc treatment of 200 patients with brain metastases: multileaf collimator size and setup uncertainties 2021 ·Strahlentherapie und Onkologie ·L. Calmels, (unknown), Patrik Sibolt, (unknown), Ulf Bjelkengren, (unknown), Poul Geertsen, C. David Sjöström, C.F. Behrens	7
9	Results of a Pilot Study on Online Adaptive Radiotherapy of Bladder Cancer with Artificial Intelligence-driven Full Re-optimization on the Anatomy of the Day 2020 ·International Journal of Radiation OncologyBiologyPhysics ·Patrik Sibolt, Lina Andersson, L. Calmels, C. David Sjöström, C.F. Behrens, Henriette Lindberg, Lone Mouritsen, Poul Geertsen	5
10	Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma 2018 ·British Journal of Cancer ·Thomas Powles, Robert J. Motzer, Bernard Escudier, Sumanta K. Pal, Christian Kollmannsberger, Joanna Pikiel, Howard Gurney, Sun Young Rha, Se Hoon Park, Poul Geertsen, Marine Gross‐Goupil, Enrique Grande, Cristina Suárez, David W. Markby, (unknown), (unknown), Toni K. Choueiri, Daniel J. George	66
11	Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials 2018 ·Annals of Oncology ·Morten Mau‐Sørensen, (unknown), Mirjam Kuipers, (unknown), Henk M.W. Verheul, Philippe Aftimos, Maja J.A. de Jonge, Baukelien van Triest, (unknown), Jürgen Debus, Esther G.C. Troost, M.A. Samuels, (unknown), Volker Budach, Sanjay Goel, Giuseppe Locatelli, Poul Geertsen	13
12	Isolated Malignant Melanoma Metastasis to the Pancreas 2013 ·Plastic & Reconstructive Surgery Global Open ·(unknown), Christen Krag, Poul Geertsen, Linda P. Jakobsen	8
13	Dosimetric and geometric evaluation of an open low-field magnetic resonance simulator for radiotherapy treatment planning of brain tumours 2008 ·Radiotherapy and Oncology ·Brian Kristensen, Finn Laursen, Vibeke Løgager, Poul Geertsen, Anders Krarup‐Hansen	41
14	Elevated serum level of YKL‐40 is an independent prognostic factor for poor survival in patients with metastatic melanoma 2006 ·Cancer ·Henrik Schmidt, Julia S. Johansen, Julie Gehl, Poul Geertsen, Kirsten Fode, Hans von der Maase	96
15	Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model 2005 ·British Journal of Cancer ·Heinz Schmidt, Lars Bastholt, Poul Geertsen, Ib Jarle Christensen, S. Larsen, Julie Gehl, Hans von der Maase	268
16	Efficient palliation of haemorrhaging malignant melanoma skin metastases by electrochemotherapy 2000 ·Melanoma Research ·Julie Gehl, Poul Geertsen	124
17	Cervical lymph node metastases from unknown primary tumours 2000 ·Radiotherapy and Oncology ·Cai Grau, Lars Vendelbo Johansen, John Jakobsen, Poul Geertsen, Elo Andersen, Brita B. Jensen	244
18	Infections in patients treated with high-dose chemotherapy for germ cell tumours 1993 ·European Journal of Cancer ·Gedske Daugaard, Hans Jørgen Nielsen, Brita Bruun, Flemming Hansen, Poul Geertsen, Henrik Carl Schønheyder	6
19	Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects. 1992 ·PubMed ·Gregers G. Hermann, Poul Geertsen, Hans von der Maase, K. Steven, C. B. Andersen, Tine Hald, Jesper Zeuthen	22
20	Major Histocompatibility Complex Class I Antigen Cross‐Linking Leads to Clonal Deletion in Human T Lymphoma Cells 1991 ·Annals of the New York Academy of Sciences ·Mogens H. Claësson, Poul Geertsen, T Tscherning	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact